Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken-Ichi Harada

Showing results (131-140 of 148) with videos related to

Pageof 15
Sort By:
International Journal of Urology : Official Journal of the Japanese Urological Association|June 22, 2023
Efficacy and safety of pembrolizumab and axitinib as first-line treatment for patients with advanced renal cell carcinoma: Real-world experience in JapanKen-Ichi Harada, Ryo Sato, Yukari Bando, et al.
Journal of Wildlife Diseases|January 29, 2011
Steatitis in egrets and herons from JapanYasuko Neagari, Suzue Arii, Mai Udagawa, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|January 24, 2023
Differential impact of proton pump inhibitor on survival outcomes of patients with advanced urothelial carcinoma treated with chemotherapy versus pembrolizumabIkko Tomisaki, Mirii Harada, Shigeru Sakano, et al.
Oncology Letters|November 11, 2024
Clinical significance of early kinetics of C‑reactive protein in patients with advanced urothelial carcinoma treated with pembrolizumab: Flare response and baseline levels predict oncological outcomesIkko Tomisaki, Mirii Harada, Shigeru Sakano, et al.
Anticancer Research|January 31, 2021
Serum Soluble Interleukin-2 Receptor as a Potential Biomarker for Immune-related Adverse EventsRyo Takai, Yohei Funakoshi, Hirotaka Suto, et al.
Anticancer Research|December 30, 2022
Association Between Body Mass Index and Outcomes in Patients With Urothelial Carcinoma Treated With PembrolizumabIkko Tomisaki, Mirii Harada, Shigeru Sakano, et al.
Marine Drugs|September 5, 2017
FVIIa-sTF and Thrombin Inhibitory Activities of Compounds Isolated from Microcystis aeruginosa K-139Andrea Roxanne J Anas, Akane Mori, Mineka Tone, et al.
Journal of Gastroenterology|February 8, 2025
A clinicopathological study of IgG4-related autoimmune hepatitis and IgG4-hepatopathyAtsushi Tanaka, Kenji Notohara, Maki Tobari, et al.
Oncology Letters|October 9, 2023
The impact of primary region resection on the therapeutic outcome of combination regimens for metastatic renal cell carcinomaJun Teishima, Takuto Hara, Taisuke Tobe, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|February 6, 2024
Therapeutic outcome of combination therapy using immune-checkpoint inhibitors and tyrosine kinase inhibitors for metastatic non-clear-cell renal cell carcinomaJun Teishima, Takuto Hara, Taisuke Tobe, et al.
Pageof 15

Showing results (131-140 of 148) with videos related to

Sort By:
Pageof 15
International Journal of Urology : Official Journal of the Japanese Urological Association|June 22, 2023
Efficacy and safety of pembrolizumab and axitinib as first-line treatment for patients with advanced renal cell carcinoma: Real-world experience in JapanKen-Ichi Harada, Ryo Sato, Yukari Bando, et al.
Journal of Wildlife Diseases|January 29, 2011
Steatitis in egrets and herons from JapanYasuko Neagari, Suzue Arii, Mai Udagawa, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|January 24, 2023
Differential impact of proton pump inhibitor on survival outcomes of patients with advanced urothelial carcinoma treated with chemotherapy versus pembrolizumabIkko Tomisaki, Mirii Harada, Shigeru Sakano, et al.
Oncology Letters|November 11, 2024
Clinical significance of early kinetics of C‑reactive protein in patients with advanced urothelial carcinoma treated with pembrolizumab: Flare response and baseline levels predict oncological outcomesIkko Tomisaki, Mirii Harada, Shigeru Sakano, et al.
Anticancer Research|January 31, 2021
Serum Soluble Interleukin-2 Receptor as a Potential Biomarker for Immune-related Adverse EventsRyo Takai, Yohei Funakoshi, Hirotaka Suto, et al.
Anticancer Research|December 30, 2022
Association Between Body Mass Index and Outcomes in Patients With Urothelial Carcinoma Treated With PembrolizumabIkko Tomisaki, Mirii Harada, Shigeru Sakano, et al.
Marine Drugs|September 5, 2017
FVIIa-sTF and Thrombin Inhibitory Activities of Compounds Isolated from Microcystis aeruginosa K-139Andrea Roxanne J Anas, Akane Mori, Mineka Tone, et al.
Journal of Gastroenterology|February 8, 2025
A clinicopathological study of IgG4-related autoimmune hepatitis and IgG4-hepatopathyAtsushi Tanaka, Kenji Notohara, Maki Tobari, et al.
Oncology Letters|October 9, 2023
The impact of primary region resection on the therapeutic outcome of combination regimens for metastatic renal cell carcinomaJun Teishima, Takuto Hara, Taisuke Tobe, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|February 6, 2024
Therapeutic outcome of combination therapy using immune-checkpoint inhibitors and tyrosine kinase inhibitors for metastatic non-clear-cell renal cell carcinomaJun Teishima, Takuto Hara, Taisuke Tobe, et al.
Pageof 15